Cytokeratin 17 mRNA as a prognostic marker of oral squamous cell carcinoma

ryoji kitamura, Takeshi Toyoshima, Hideaki Tanaka, Shintarou Kawano, Ryota Matsubara, Yuichi Goto, Teppei Jinno, Yasuyuki Maruse, Kazunari Oobu, Seiji Nakamura

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Despite diagnostic and therapeutic advances, the 5-year survival rate of oral squamous cell carcinoma (OSCC) remains between 70-80% due to recurrences and secondary metastases to cervical lymph nodes. It is difficult to find these recurrences and metastases postoperatively, thus, careful follow-up is recommended. Cytokeratins (CKs) are intermediate filaments of the cytoskeleton and candidate prognostic biomarkers for OSCC, as they are overexpressed in OSCC compared with normal mucosa. The aim of the present study was to determine the relative levels of occurrence of 3 CK mRNA (CK17, CK19, CK20) transcripts in peripheral blood mononuclear cells (PBMC) using reverse transcription-quantitative polymerase chain reaction. The study comprised preand post-operative PBMC samples from 19 OSCC patients. In the good-prognosis group, 10 of 13 patients demonstrated reduced CK17 mRNA expression post-operatively, compared with pre-operative samples, conversely, only 3 of 6 patients in the poor-prognosis group had reduced post-operative CK17 mRNA expression. This difference was statistically significant (P<0.01). The disease-free survival rate of the group with reduced post-operative CK17 mRNA expression was significantly increased compared with the elevated CK17 mRNA group (P<0.01); however, the overall survival rates of the two groups were not significantly different. Neither CK19 mRNA nor CK20 mRNA were significantly expressed in the PBMC of OSCC patients. Overall, CK17 mRNA expression may be a useful prognostic biomarker for OSCC.

元の言語英語
ページ(範囲)6735-6743
ページ数9
ジャーナルOncology Letters
14
発行部数6
DOI
出版物ステータス出版済み - 12 1 2017

Fingerprint

Keratin-17
Squamous Cell Carcinoma
Messenger RNA
Blood Cells
Survival Rate
Keratin-3
Biomarkers
Neoplasm Metastasis
Recurrence
Intermediate Filaments
Keratins
Cytoskeleton
Reverse Transcription
Disease-Free Survival
Mucous Membrane
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Cytokeratin 17 mRNA as a prognostic marker of oral squamous cell carcinoma. / kitamura, ryoji; Toyoshima, Takeshi; Tanaka, Hideaki; Kawano, Shintarou; Matsubara, Ryota; Goto, Yuichi; Jinno, Teppei; Maruse, Yasuyuki; Oobu, Kazunari; Nakamura, Seiji.

:: Oncology Letters, 巻 14, 番号 6, 01.12.2017, p. 6735-6743.

研究成果: ジャーナルへの寄稿記事

@article{fdc57334af334802988a0b92d2e9dd0f,
title = "Cytokeratin 17 mRNA as a prognostic marker of oral squamous cell carcinoma",
abstract = "Despite diagnostic and therapeutic advances, the 5-year survival rate of oral squamous cell carcinoma (OSCC) remains between 70-80{\%} due to recurrences and secondary metastases to cervical lymph nodes. It is difficult to find these recurrences and metastases postoperatively, thus, careful follow-up is recommended. Cytokeratins (CKs) are intermediate filaments of the cytoskeleton and candidate prognostic biomarkers for OSCC, as they are overexpressed in OSCC compared with normal mucosa. The aim of the present study was to determine the relative levels of occurrence of 3 CK mRNA (CK17, CK19, CK20) transcripts in peripheral blood mononuclear cells (PBMC) using reverse transcription-quantitative polymerase chain reaction. The study comprised preand post-operative PBMC samples from 19 OSCC patients. In the good-prognosis group, 10 of 13 patients demonstrated reduced CK17 mRNA expression post-operatively, compared with pre-operative samples, conversely, only 3 of 6 patients in the poor-prognosis group had reduced post-operative CK17 mRNA expression. This difference was statistically significant (P<0.01). The disease-free survival rate of the group with reduced post-operative CK17 mRNA expression was significantly increased compared with the elevated CK17 mRNA group (P<0.01); however, the overall survival rates of the two groups were not significantly different. Neither CK19 mRNA nor CK20 mRNA were significantly expressed in the PBMC of OSCC patients. Overall, CK17 mRNA expression may be a useful prognostic biomarker for OSCC.",
author = "ryoji kitamura and Takeshi Toyoshima and Hideaki Tanaka and Shintarou Kawano and Ryota Matsubara and Yuichi Goto and Teppei Jinno and Yasuyuki Maruse and Kazunari Oobu and Seiji Nakamura",
year = "2017",
month = "12",
day = "1",
doi = "10.3892/ol.2017.7066",
language = "English",
volume = "14",
pages = "6735--6743",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Cytokeratin 17 mRNA as a prognostic marker of oral squamous cell carcinoma

AU - kitamura, ryoji

AU - Toyoshima, Takeshi

AU - Tanaka, Hideaki

AU - Kawano, Shintarou

AU - Matsubara, Ryota

AU - Goto, Yuichi

AU - Jinno, Teppei

AU - Maruse, Yasuyuki

AU - Oobu, Kazunari

AU - Nakamura, Seiji

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Despite diagnostic and therapeutic advances, the 5-year survival rate of oral squamous cell carcinoma (OSCC) remains between 70-80% due to recurrences and secondary metastases to cervical lymph nodes. It is difficult to find these recurrences and metastases postoperatively, thus, careful follow-up is recommended. Cytokeratins (CKs) are intermediate filaments of the cytoskeleton and candidate prognostic biomarkers for OSCC, as they are overexpressed in OSCC compared with normal mucosa. The aim of the present study was to determine the relative levels of occurrence of 3 CK mRNA (CK17, CK19, CK20) transcripts in peripheral blood mononuclear cells (PBMC) using reverse transcription-quantitative polymerase chain reaction. The study comprised preand post-operative PBMC samples from 19 OSCC patients. In the good-prognosis group, 10 of 13 patients demonstrated reduced CK17 mRNA expression post-operatively, compared with pre-operative samples, conversely, only 3 of 6 patients in the poor-prognosis group had reduced post-operative CK17 mRNA expression. This difference was statistically significant (P<0.01). The disease-free survival rate of the group with reduced post-operative CK17 mRNA expression was significantly increased compared with the elevated CK17 mRNA group (P<0.01); however, the overall survival rates of the two groups were not significantly different. Neither CK19 mRNA nor CK20 mRNA were significantly expressed in the PBMC of OSCC patients. Overall, CK17 mRNA expression may be a useful prognostic biomarker for OSCC.

AB - Despite diagnostic and therapeutic advances, the 5-year survival rate of oral squamous cell carcinoma (OSCC) remains between 70-80% due to recurrences and secondary metastases to cervical lymph nodes. It is difficult to find these recurrences and metastases postoperatively, thus, careful follow-up is recommended. Cytokeratins (CKs) are intermediate filaments of the cytoskeleton and candidate prognostic biomarkers for OSCC, as they are overexpressed in OSCC compared with normal mucosa. The aim of the present study was to determine the relative levels of occurrence of 3 CK mRNA (CK17, CK19, CK20) transcripts in peripheral blood mononuclear cells (PBMC) using reverse transcription-quantitative polymerase chain reaction. The study comprised preand post-operative PBMC samples from 19 OSCC patients. In the good-prognosis group, 10 of 13 patients demonstrated reduced CK17 mRNA expression post-operatively, compared with pre-operative samples, conversely, only 3 of 6 patients in the poor-prognosis group had reduced post-operative CK17 mRNA expression. This difference was statistically significant (P<0.01). The disease-free survival rate of the group with reduced post-operative CK17 mRNA expression was significantly increased compared with the elevated CK17 mRNA group (P<0.01); however, the overall survival rates of the two groups were not significantly different. Neither CK19 mRNA nor CK20 mRNA were significantly expressed in the PBMC of OSCC patients. Overall, CK17 mRNA expression may be a useful prognostic biomarker for OSCC.

UR - http://www.scopus.com/inward/record.url?scp=85032706741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032706741&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.7066

DO - 10.3892/ol.2017.7066

M3 - Article

VL - 14

SP - 6735

EP - 6743

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 6

ER -